Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Retrieved on: 2023-12-18 23:15:18

Tags for this article:

Medical physics

Eli Lilly and Company

Research and development in the United States

Radiation therapy

Lutetium (177Lu) vipivotide tetraxetan

Prostate cancer

Clinical trial

Click the tags to see associated articles and topics

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint. View article details on hiswai:

Excerpt

Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto ...

Article found on: medcitynews.com

View Original Article